Cargando…

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis

BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Philippa, Yuan, Ji, Ahmed, Fahad Shabbir, McHenry, Austin, Fu, Kai, Yu, Guohua, Cheng, Hongxia, Xu, Mina L., Rimm, David L., Pan, Zenggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435777/
https://www.ncbi.nlm.nih.gov/pubmed/34527580
http://dx.doi.org/10.3389/fonc.2021.701492
_version_ 1783751869710991360
author Li, Philippa
Yuan, Ji
Ahmed, Fahad Shabbir
McHenry, Austin
Fu, Kai
Yu, Guohua
Cheng, Hongxia
Xu, Mina L.
Rimm, David L.
Pan, Zenggang
author_facet Li, Philippa
Yuan, Ji
Ahmed, Fahad Shabbir
McHenry, Austin
Fu, Kai
Yu, Guohua
Cheng, Hongxia
Xu, Mina L.
Rimm, David L.
Pan, Zenggang
author_sort Li, Philippa
collection PubMed
description BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse large B-cell lymphomas (DLBCL). While mantle cell lymphoma (MCL) is well-known to contain frequent epithelioid macrophages, LAM characterization within MCL has not been fully described. Herein we evaluate the immunophenotypic subclassification, the expression of immune checkpoint molecule PD-L1, and the prognostic impact of LAMs in MCL. MATERIALS AND METHODS: A total of 82 MCL cases were collected and a tissue microarray block was constructed. Immunohistochemical staining was performed using CD68 and CD163, and the positive cells were recorded manually in four representative 400× fields for each case. Multiplexed quantitative immunofluorescence assays were carried out to determine PD-L1 expression on CD68+ M1 LAMs and CD163+ M2 LAMs. In addition, we assessed Ki67 proliferation rate of MCL by an automated method using the QuPath digital imaging analysis. The cut-off points of optimal separation of overall survival (OS) were analyzed using the X-Tile software, the SPSS version 26 was used to construct survival curves, and the log-rank test was performed to calculate the p-values. RESULTS: MCL had a much higher count of M1 LAMs than M2 LAMs with a CD68:CD163 ratio of 3:1. Both M1 and M2 LAMs were increased in MCL cases with high Ki67 proliferation rates (>30%), in contrast to those with low Ki67 (<30%). Increased number of M1 or M2 LAMs in MCL was associated with an inferior OS. Moreover, high expression of PD-L1 on M1 LAMs had a slightly better OS than the cases with low PD-L1 expression, whereas low expression of PD-L1 on M2 LAMs had a slightly improved OS, although both were not statistically significant. CONCLUSIONS: In contrast to DLBCL, MCL had a significantly lower rate of M1 to M2 polarization, and the high levels of M1 and M2 LAMs were associated with poor OS. Furthermore, differential PD-L1 expressions on LAMs may partially explain the different functions of tumor-suppressing or tumor-promoting of M1 and M2 LAMs, respectively.
format Online
Article
Text
id pubmed-8435777
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84357772021-09-14 High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis Li, Philippa Yuan, Ji Ahmed, Fahad Shabbir McHenry, Austin Fu, Kai Yu, Guohua Cheng, Hongxia Xu, Mina L. Rimm, David L. Pan, Zenggang Front Oncol Oncology BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse large B-cell lymphomas (DLBCL). While mantle cell lymphoma (MCL) is well-known to contain frequent epithelioid macrophages, LAM characterization within MCL has not been fully described. Herein we evaluate the immunophenotypic subclassification, the expression of immune checkpoint molecule PD-L1, and the prognostic impact of LAMs in MCL. MATERIALS AND METHODS: A total of 82 MCL cases were collected and a tissue microarray block was constructed. Immunohistochemical staining was performed using CD68 and CD163, and the positive cells were recorded manually in four representative 400× fields for each case. Multiplexed quantitative immunofluorescence assays were carried out to determine PD-L1 expression on CD68+ M1 LAMs and CD163+ M2 LAMs. In addition, we assessed Ki67 proliferation rate of MCL by an automated method using the QuPath digital imaging analysis. The cut-off points of optimal separation of overall survival (OS) were analyzed using the X-Tile software, the SPSS version 26 was used to construct survival curves, and the log-rank test was performed to calculate the p-values. RESULTS: MCL had a much higher count of M1 LAMs than M2 LAMs with a CD68:CD163 ratio of 3:1. Both M1 and M2 LAMs were increased in MCL cases with high Ki67 proliferation rates (>30%), in contrast to those with low Ki67 (<30%). Increased number of M1 or M2 LAMs in MCL was associated with an inferior OS. Moreover, high expression of PD-L1 on M1 LAMs had a slightly better OS than the cases with low PD-L1 expression, whereas low expression of PD-L1 on M2 LAMs had a slightly improved OS, although both were not statistically significant. CONCLUSIONS: In contrast to DLBCL, MCL had a significantly lower rate of M1 to M2 polarization, and the high levels of M1 and M2 LAMs were associated with poor OS. Furthermore, differential PD-L1 expressions on LAMs may partially explain the different functions of tumor-suppressing or tumor-promoting of M1 and M2 LAMs, respectively. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435777/ /pubmed/34527580 http://dx.doi.org/10.3389/fonc.2021.701492 Text en Copyright © 2021 Li, Yuan, Ahmed, McHenry, Fu, Yu, Cheng, Xu, Rimm and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Philippa
Yuan, Ji
Ahmed, Fahad Shabbir
McHenry, Austin
Fu, Kai
Yu, Guohua
Cheng, Hongxia
Xu, Mina L.
Rimm, David L.
Pan, Zenggang
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title_full High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title_fullStr High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title_full_unstemmed High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title_short High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
title_sort high counts of cd68+ and cd163+ macrophages in mantle cell lymphoma are associated with inferior prognosis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435777/
https://www.ncbi.nlm.nih.gov/pubmed/34527580
http://dx.doi.org/10.3389/fonc.2021.701492
work_keys_str_mv AT liphilippa highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT yuanji highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT ahmedfahadshabbir highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT mchenryaustin highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT fukai highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT yuguohua highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT chenghongxia highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT xuminal highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT rimmdavidl highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis
AT panzenggang highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis